<DOC>
	<DOC>NCT00366548</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine manufactured with Polysorbate 80 compared to a 13-valent pneumococcal conjugate (13vPnC) manufactured without Polysorbate 80 when given concomitantly with routine paediatric vaccinations.</brief_summary>
	<brief_title>Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criteria: 1. Aged 2 months (42 through 98 days) at the time of enrollment. 2. Available for the entire study period and whose parent(s)/legal guardian(s) could be reached by telephone. 3. In good health as determined by medical history, physical examination, and judgment of the investigator. 4. Parent(s)/legal guardian(s) were able to complete all relevant study procedures during study participation. Exclusion criteria: 1. Previous vaccination with licensed or investigational pneumococcal vaccine. 2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, or polio vaccines. 3. A previous anaphylactic reaction to any vaccine or vaccinerelated component. 4. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, hepatitis B, or pneumococcal vaccines. 5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection. 6. Known or suspected immune deficiency or suppression. 7. History of cultureproven invasive disease caused by S pneumoniae. 8. Major known congenital malformation or serious chronic disorder. 9. Significant neurological disorder or history of seizure (including febrile seizure), or significant stable or evolving disorders (such as cerebral palsy, encephalopathy, or hydrocephalus), or other significant disorders. This did not include resolving syndromes because of birth trauma such as Erb palsy. 10. Receipt of blood products or Î³globulin (including hepatitis B immunoglobulin and monoclonal antibodies [eg, Synagis]).</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>98 Days</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Infant</keyword>
</DOC>